MedTrace Logo

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

NCT01233245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1077

Last updated 2012-11-15

No results posted yet for this study

Summary

This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors. The patients were evaluated under normal clinical practice and were asked to fill out the quality of life FAMS questionnaire, Coping processes (WCQ - Ways of Coping Questionnaire) and depression questionnaire CES-D.

Conditions

  • Relapsing Remitting MS (RRMS)
  • Secondary Progressive MS (SPMS)

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

250 µg, sub-cutaneously, on alternate days

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Czechia
  • France
  • Germany
  • Iran
  • Israel
  • Italy
  • Jordan
  • Lebanon
  • Netherlands
  • Portugal
  • Saudi Arabia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233245 on ClinicalTrials.gov